MainBoardListed
Glenmark Life Sciences Limited
Company websiteThe company Glenmark Life Sciences Limited has filed papers to raise ₹2,10,22,222 crore through a public issue. The offering includes a fresh tranche of ₹1,47,22,222 crore and OFS of ₹63,00,000 crore.
Investors may apply between 27-07-2021 and 29-07-2021. Expected allotment is on 03-08-2021 and listing is aimed for 06-08-2021. This is a standard structure — fresh capital for growth, OFS for seller liquidity.
Start Date27-07-2021
End Date29-07-2021
Listing Date06-08-2021
Allotment Date03-08-2021
Current Price₹750
GMP₹82 (11.39%)
Lot Size20 Shares
Subscription0 Times
Face Value₹2 per share
Listing atNSE, BSE
Issue Price₹695-₹720
Pre Issue₹10,78,04,950
Post Issue₹12,25,27,172
Issue Size₹2,10,22,222
(aggregating up to 1514.00 Cr)
(aggregating up to 1514.00 Cr)
Fresh Issue₹1,47,22,222
(aggregating up to 1060.00 Cr)
(aggregating up to 1060.00 Cr)
Offer For Sale₹63,00,000
(aggregating up to 454.00 Cr)
(aggregating up to 454.00 Cr)
The Grey Market Premium (GMP) for Glenmark Life Sciences Limited is currently around ₹82 (11.39%). This indicates an estimated listing price of approximately ₹777 based on the latest market sentiment. Please note that GMP values are unofficial and can change frequently as they depend on demand, market conditions, and investor activity.
Gmp Details
| Last Updated | IPO Price | GMP | Estimated Listing Price |
|---|---|---|---|
14 Apr 2025, 10:17 | ₹720 | ₹82 | ₹802 (11.39%) |
Financials overview In Lakhs
Here is a quick look at the recent financial performance of Glenmark Life Sciences Limited . The numbers below ( In Lakhs ) show how the company’s revenue and profits have changed over the last few years. This helps investors understand how strongly the business is growing and how stable its financial health is before applying for the IPO.
The IPO reservation for Glenmark Life Sciences Limited shows how the total issue is divided among different investor categories. This includes allocations for Retail Investors, Qualified Institutional Buyers (QIBs), and Non-Institutional Investors (NIIs). Understanding the reservation structure helps investors know how much of the issue is set aside for their category before applying.
IPO Reservation
| Category | Shares Offers | No. of Shares |
|---|---|---|
QIB | 38.46% | 1,05,11,110 |
Anchor | 23.08% | 63,06,660 |
NII (HNI) | 11.54% | 31,53,334 |
RETAIL | 26.92% | 73,57,778 |
TOTAL | 100.00% | 2,73,28,882 |
Lot(s) Distribution
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
Retail (Min) | 1 | 20 | ₹14,400 | |
sHNI | 13 | 280 | ₹2,01,600 | |
bHNI | 70 | 1,400 | ₹10,08,000 |
Below you can find the official contact details of Glenmark Life Sciences Limited along with the registrar handling the IPO process. This information helps investors reach out for queries related to the company or for checking the allotment status and application updates once the IPO process begins.
Company Details
Phone: +91 2189 234456
Website: http://www.glenmarklifesciences.com/
Address: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur 413 213,